Ms. Michele Ann O'neill, M.S.W. Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2877 Spear St, Charlotte, VT 05445 Phone: 802-865-3450 |
Ms. Myra Handy, LICSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 3117 Guinea Rd, Charlotte, VT 05445 Phone: 802-999-7983 |
Kimberly M Ziegelman, LICSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 528 Stockbridge Rd, Charlotte, VT 05445 Phone: 802-999-1330 |
News Archive
A series of 15 scientific papers published this week in the journals of the Genetics Society of America (Genetics and G3: Genes|Genomes|Genetics) put North Carolina at the epicenter of a scientific resource called the Collaborative Cross - a "library" of genetic diversity that scientists believe can help fast-track important discoveries about genetics and disease into new discoveries, tests, and treatments that impact human health.
In May 2009 RaySearch Laboratories entered into a long-term development and licensing agreement with Siemens Healthcare. Under the agreement RaySearch provided a number of treatment planning modules for integration in Siemens' syngo Suite for Oncology, which is Siemens' integrated workflow solution for radiation therapy.
A popular indigestion medication can increase survival in colorectal cancer, according to research published in ecancermedicalscience. But in fact, scientists have studied this for years - and a group of cancer advocates want to know why this research isn't more widely used.
To create treatments for a disease without any, scientists need to study and understand the driving forces behind the faulty biology. Today, researchers at the University of North Carolina School of Medicine announced the first-ever evidence-based description of the neuronal protein clumps thought to be important in Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, a fatal neurodegenerative condition.
The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a Phase Ib/II study of bendamustine (Treanda®), an anticancer agent currently approved for the treatment of chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin's lymphoma (NHL), in combination with lenalidomide (Revlimid®) and dexamethasone in patients with relapsed multiple myeloma. The trial, led by Shaji Kumar, MD, of Mayo Clinic, is open for enrollment at Mayo Clinic (Rochester, Minn.), City of Hope Cancer Center (Duarte, Calif.) and the University of Chicago (Chicago, Ill).
› Verified 2 days ago